AGP

CY21 Result Review: BUY Stance Maintained



Equity Research | Pharmaceuticals | Monday, 28 March, 2022

AGP has announced its CY21 result where it posted profit after tax of Rs1.565bn (EPS: Rs5.59) as compared to profit after tax of Rs1.587bbn (EPS: Rs5.67) in the same period last year, down by 1.4% YoY.

The company has posted a revenue of Rs7.420bn against Rs6.946bn in SPLY, recording a growth of 6.8% YoY. We note that this surge is attributed to the increase in volumetric sales.

The gross margin has been decreased to 55.5% as compared to 55.6% during SPLY on account of higher input cost.

SG&A expenses have been increased by 15% YoY to Rs1.615bn as compared to Rs1.404mn during SPLY.


Finance cost has been decreased by 41% YoY to Rs89mn as compared to Rs152mn during SPLY.

Lastly, the effective taxation has been increased to 18.1% as compared to 17.6% during SPLY.

AGP is currently trading at CY22E PE of 10.29x. Further, the scrip is also trading at CY22E PB of 2.17x which offers a discount of 22% relative to its 3-year historical average of 2.78%. We have a **BUY** stance on the scrip with a DCF based Dec-22 TP of Rs105 which provides an upside potential of 28%. Furthermore, it also offers a dividend yield of 4% which makes a total return of 32%.

Rupees' millions	4QCY21	4QCY20	YoY	CY21	CY20	YoY
Net Sales	2,226	1,955	13.8% ▲	7,420	6,946	6.8% ▲
Cost of Sales	907	787	15.3% ▲	3,303	3,086	7.0% ▲
Gross Profit	1,319	1,168	12.9% ▲	4,117	3,861	6.6% ▲
SG&A Expenses	569	603	5.6% ▼	1,615	1,404	15.0% ▲
Other Expenses	46	35	30.0% ▲	157	183	14.2% ▼
Operating Profit	704	530	32.7% ▲	1,955	2,047	4.5% ▼
Other Income	-6	12	145.9% ▼	46	32	46.0% ▲
Finance Cost	17	30	45.0% ▼	89	152	41.2% ▼
Profit Before Taxation	682	512	33.1% ▲	1,911	1,927	0.8% ▼
Taxation	136	94	44.9% ▲	346	339	2.1% ▲
Profit After Taxation	546	418	30.4% ▲	1,565	1,587	1.4% ▼
Earnings Per Share	1.95	1.49	30.4% ▲	5.59	5.67	1.4% ▼
Dividend	2.50	1.00		2.50	2.00	
Bonus	0%	0%		0%	0%	
	Closing	g Period: April 1	9, 2022 - April 2	6, 2022		
Gross Margin	59.2%	59.8%	0.5% ▼	55.5%	55.6%	0.1% ▼
SG&A Expenses to Sales	25.6%	30.8%	5.3% ▼	21.8%	20.2%	1.6% ▲
Other Expenses to Sales	2.0%	1.8%	0.3% ▲	2.1%	2.6%	0.5% ▼
Other Income to Sales	-0.2%	0.6%	0.9% ▼	0.6%	0.5%	0.2% ▲
Effective Taxation	19.9%	18.3%	1.6% ▲	18.1%	17.6%	0.5% ▲
Net Margin	24.5%	21.4%	3.1% ▲	21.1%	22.9%	1.8% ▼

Source: ACPL Research, Company Financials



Financial Projections

Rupees' millions	CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Net sales	6,253	6,946	7,420	9,054	9,706	10,404	11,153
Cost of sale	2,594	3,086	3,303	3,694	3,960	4,245	4,551
Gross profit	3,659	3,861	4,117	5,360	5,746	6,159	6,603
Administration expenses	158	227	391	366	392	420	451
Marketing and selling expenses	1,294	1,404	1,615	1,950	2,091	2,241	2,402
Other operating expenses	167	183	157	186	199	213	229
Operating Profit	2,040	2,047	1,955	2,858	3,064	3,285	3,521
Other operating income	11	32	46	27	29	31	33
Finance cost	227	152	89	99	220	228	239
Profit before taxation	1,825	1,927	1,911	2,787	2,873	3,088	3,315
Taxation	378	339	346	555	573	615	661
Profit after taxation	1,446	1,587	1,565	2,231	2,300	2,472	2,655
EPS	5.17	5.67	5.59	7.97	8.22	8.83	9.48

Source: ACPL Research, Company Financials

Horizontal Analysis

	CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
Net sales	16.2%	11.1%	6.8%	22.0%	7.2%	7.2%	7.2%
Cost of sale	10.8%	19.0%	7.0%	11.8%	7.2%	7.2%	7.2%
Gross profit	20.3%	5.5%	6.6%	30.2%	7.2%	7.2%	7.2%
Administration expenses	24.1%	43.6%	72.4%	-6.4%	7.2%	7.2%	7.2%
Marketing and selling expenses	12.2%	8.5%	15.0%	20.8%	7.2%	7.2%	7.2%
Other operating expenses	10.2%	9.7%	-14.2%	18.1%	7.2%	7.2%	7.2%
Operating Profit	26.8%	0.3%	-4.5%	46.2%	7.2%	7.2%	7.2%
Other operating income	-33.6%	180.4%	46.0%	-41.1%	7.2%	7.2%	7.2%
Finance cost	13.5%	-33.1%	-41.2%	10.6%	122.9%	3.6%	4.8%
Profit before taxation	28.0%	5.6%	-0.8%	45.8%	3.1%	7.5%	7.4%
Taxation	72.8%	-10.3%	2.1%	60.3%	3.1%	7.5%	7.4%
Profit after taxation	19.9%	9.8%	-1.4%	42.6%	3.1%	7.5%	7.4%
EPS	19.9%	9.8%	-1.4%	42.6%	3.1%	7.5%	7.4%

Source: ACPL Research, Company Financials

Key Ratios

Profitability Ratios		CY19A	CY20A	CY21E	CY22E	CY23E	CY24E	CY25E
GP Margin	%	58.52	55.58	55.49	59.20	59.20	59.20	59.20
NP Margin	%	23.13	22.85	21.09	24.64	23.70	23.76	23.80
OP Margin	%	32.63	29.47	26.34	31.57	31.57	31.57	31.57
ROE	%	19.38	19.33	16.78	21.10	19.45	18.76	18.13
ROCE	%	17.53	18.28	15.63	20.49	19.31	18.68	18.06
ROA	%	15.06	15.58	13.04	15.11	13.41	12.46	11.66
Liquidity Ratios		CY19A	CY20A	CY21E	CY22E	CY23E	CY24E	CY25E
Current	x	1.64	1.71	3.56	3.41	4.45	5.34	6.14
Acid-test	х	1.14	1.25	1.54	1.47	1.57	1.59	1.59
Cash to current liab.	Х	0.09	0.25	1.69	1.49	2.41	3.29	4.10
Activity Ratios		CY19A	CY20A	CY21E	CY22E	CY23E	CY24E	CY25E
Inventory Turnover	Х	3	3	3	2	2	2	2
Inventory Days		143	140	143	200	200	200	200
Receivables Days		33	39	32	44	41	41	41
Payables Days		119	119	119	200	200	200	200
Operating Cycle		56	60	55	44	41	41	41
Investment Ratios		CY19A	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E
EPS	Rs.	5.17	5.67	5.59	7.97	8.22	8.83	9.48
DPS	Rs.	3.25	2.00	2.50	3.50	3.75	4.00	4.25
Div. Yield	%	3.96	2.44	3.05	4.27	4.57	4.88	5.18
Dividend Cover	х	1.59	2.83	2.24	2.28	2.19	2.21	2.23
BVPS	Rs.	26.65	29.32	33.31	37.78	42.24	47.07	52.30
Payout	%	62.92	35.28	44.73	43.92	45.64	45.30	44.83
Retention	%	37.08	64.72	55.27	56.08	54.36	54.70	55.17
No. of Shares	mn	280	280	280	280	280	280	280
P/E		15.87	14.46	14.67	10.29	9.98	9.29	8.65
Sales per share		22.33	24.81	26.50	32.34	34.66	37.16	39.83
P/BV		3.08	2.80	2.46	2.17	1.94	1.74	1.57
Price to Sales		4.77	4.29	4.02	3.29	3.07	2.87	2.67
		0140	0.400	0.045	0,400	0,400	0.42.45	
Gearing Ratios		CY19A	CY20A	CY21E	CY22E	CY23E	CY24E	CY25E
Debt to Equity	Х	19.29	12.97	9.27	4.63	0.45	0.00	0.00
Interest Cover	Х	8.99	13.48	21.89	28.94	13.91	14.40	14.73

Source: ACPL Research, Company Financials

This report has been prepared by Abbasi & Company (Private) Limited and is provided for information purposes only. Under no circumstances, this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, Abbasi & Company (Private) Limited and or any of its officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and Abbasi & Company (Private) Limited accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of Abbasi & Company (Private) Limited Research Department and do not necessarily reflect those of the company or its directors. Abbasi & Company (Private) Limited as a firm may have business relationships, including investment--banking relationships, with the companies referred to in this report. Abbasi & Company (Private) Limited does not act as a market maker in the securities of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives do not have a financial interest in the securities of the subject company to an amount exceeding 1% of the value of the securities of the subject company at the time of issuance of this report. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives are not currently serving or have served in the past three years as a director or officer of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives have not received compensation from the subject company in the previous 12 months. The subject company currently is not, or during the 12-month period preceding the date of publication or distribution of this report, was not, a client of Abbasi & Company (Private) Limited. We have not managed or co-managed a public offering or any take-over, buyback or delisting offer of securities for the subject company in the past 12 months and/or received compensation for corporate advisory services, brokerage services or underwriting services from the subject company in the past 12 months. Abbasi & Company (Private) Limited does not expect to receive or intend to seek compensation for corporate advisory services or underwriting services from the subject company in the next 3 months

All rights reserved by Abbasi & Company (Private) Limited. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of Abbasi & Company (Private) Limited. Action could be taken for unauthorized reproduction, distribution or publication

VALIDITY OF THE PUBLICATION OR REPORT

The information in this publication or report is, regardless of source, given in good faith, and may only be valid as of the stated date of this publication or report. The information may be subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company, jurisdiction or financial instruments referred to in this report. The valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report and were based upon several estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein is not to be relied upon as a representation and/or warranty by Abbasi & Company (Private) Limited and/or its other associated and affiliated companies, that:

- I. Such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- II. There is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein

DEFINITION OF TERMS

TP	Target Price	CAGR	Compound Annual Growth Rate	FCF	Free Cash Flows
FCFE	Free Cash Flows to Equity	FCFF	Free Cash Flows to Firm	DCF	Discounted Cash Flows
PE	Price to Earnings Ratio	PB	Price to Book Ratio	BVPS	Book Value Per Share
EPS	Earnings Per Share	DPS	Dividend Per Share	ROE	Return of Equity
ROA	Return on Assets	SOTP	Sum of the Parts	LDCP	Last Day Closing Price

VALUATION METHODOLOGY

To arrive at our Target Price, Abbasi & Company (Private) Limited uses different valuation methods which include:

- I. Discounted Cash Flow Model
- II. Dividend Discount Model
- III. Relative Valuation Model
- IV. Sum of Parts Valuation

RATINGS CRITERIA

Abbasi & Company (Private) Limited employs a three-tier ratings system to rate a stock and sector, as mentioned below, which is based upon the level of expected return for a specific stock and outlook of sector. The rating is based on the following with stated time horizon

Stock Rating	Expected Total Return
BUY	Greater than 15%
HOLD	Between -5% to 15%
SELL	Less than and equal to -5%

Sector Rating	Sector Outlook
Overweight	Positive
Market Weight	Neutral
Underweight	Negative

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

RESEARCH DISSEMINATION POLICY

Abbasi & Company (Private) Limited endeavors to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc. Nevertheless, all clients may not receive the material at the same time

OTHER DISCLOSURES

The research analyst is primarily involved in the preparation of this report, certifies that:

- I. The views expressed in this report accurately reflect his/her personal views about the subject company/stock /sector and economy
- II. No part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report

The Research Analyst is not and was not involved in issuing of a research report on any of the subject company's associated companies

RESEARCH DEPARTMENT

6 - Shadman, Lahore

Phone: (+92) 42 38302028; Ext 116, 117 Email: research@abbasiandcompany.com web: www.abbasiandcompany.com

HEAD OFFICE

6 - Shadman, Lahore

Phone: (+92) 42 38302028

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com

BRANCH OFFICE

42 - Mall Road, Lahore

Phone: (+92) 42 37320707

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com